论文共同通讯作者、英矽智能创始人兼首席执行官 Alex Zhavoronkov 博士表示，多达 85% ...

在对KRAS成功研究的基础上，研究人员正在将他们的量子-经典混合模型应用于其他“不可成药”的蛋白。与KRAS类似，这些蛋白质通常很小，表面缺乏轮廓，使分子难以与之结合。研究小组还计划利用混合模型进一步对两款KRAS的苗头化合物展开进一步的优化设计，旨在动物模型中进一步验证具有前景的新型KRAS抑制剂。

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

KRAS突变是癌症中常见的突变之一，出现在大约四分之一的人类肿瘤中。KRAS突变会导致细胞不受控制的增殖进而引发癌症。尽管KRAS突变非常普遍且影响巨大，但目前只有两种专门针对突变KRAS的药物获得了美国食品及药物管理局（FDA）的批准。而且，临床数据显示，与传统化疗相比，这些药物仅能延长患者几个月的生命。改良KRAS靶向疗法，使它为癌症患者带来更多的获益， ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.